Participated · Series A · Mar 2024

CyberSaint's CyberStrong platform uses patented AI to automate compliance, quantify cyber risk in financial terms, and align security programs with executive and board priorities. The platform includes features such as a Free Cyber Risk Analysis tool and recent remediation enhancements to optimize resource allocation and decision-making. CyberSaint has become a standard for cyber risk management across the Fortune 500 and announced a partnership with IBM Cloud's Security & Compliance Center. Since launching in 2016, the company has received industry recognition including Snowflake's State of Next‑Generation Cybersecurity Applications Report and Gartner’s Innovation Insight on Continuous Control Monitoring. The company plans to use new funding to build on customer momentum, accelerate global market expansion, and continue innovation of CyberStrong. Leadership additions such as Chief Product Officer Matt Alderman will lead product strategy and development initiatives. CyberSaint Security develops the CyberStrong platform, an integrated risk management solution that automates cybersecurity compliance, assessments, remediation planning, and reporting using AI and machine learning. The platform is built on the NIST Cybersecurity Framework and provides a single pane of glass for CISOs and security teams to measure, report, and mitigate risk. In 2018 the company reported record growth — a more than 400% increase in bookings in Q4 and 1100% growth in its customer base — and completed a $3 million funding round in March 2018 that the company said propelled expansion. CyberSaint expanded engineering, sales, and marketing teams by over 200%, added more than 10 partners to its partner program, moved its headquarters to the Boston Seaport Innovation District, and expanded its user base to three new continents. The company was awarded a patent for its AI and algorithms that automate risk mitigation action planning and emphasizes rapid time-to-value and automation to replace manual GRC processes.

Led · Series C · Jul 2021

Virsec provides the Virsec Security Platform (VSP), which stops sophisticated attacks at their first point of insurgence and prevents adversaries from gaining dwell time in software. The platform delivers in-depth visibility across entire workloads and detects and blocks known and unknown threats that can evade heuristic and endpoint solutions. VSP maps the expected performance of each application on a workload, protects the memory applications use to execute, and ensures application components are correct and unmodified before execution; deviations are treated as threats. Led by CEO Dave Furneaux, the company intends to use newly raised funds to expand operations and its business reach. The raise brought the company’s total funding to $137M. Virsec has developed a technology platform that protects critical applications from the inside, safeguarding processes in memory and pinpointing attacks in real time. Its patented Trusted Execution™ technology maps acceptable application execution and instantly detects deviations caused by attacks. The solution has been deployed and gone through extensive validation with early-adopter customers in critical infrastructure, defense, financial services, and healthcare. The company holds a portfolio of patents with more than 20 applications filed and 12 already granted. Virsec is led by CEO Atiq Raza. It plans to use the new funding to accelerate product innovation and global expansion.

Led · Seed · Sep 2019

Wallit (formerly Ourly) is a free rewards-based savings app designed for families with teens that rewards users when they save and spend. The app connects to any U.S. bank or credit union and includes a bank-issued spending card from partner banks for instant transfers, online/in-store shopping and moment-based cash rewards tied to goals. Wallit's features let teens and parents manage money together and earn cash rewards on everyday saving and spending. The company has more than 20,000 monthly active users. Wallit intends to use new funding to expand its core product, drive sales and marketing initiatives, and increase channel partnerships. The company was founded in 2016 and maintains offices in Portland, Maine and Boston.

Led · Equity · Jan 2019

GreenLight Biosciences develops low-cost, scalable RNA products using a patented, cell-free bioprocessing platform to enable commercial RNA applications in agriculture and life sciences. The company aims to commercialize a pipeline of RNA-based agricultural biocontrols and expand into RNA-based therapeutics and vaccines. Its platform dramatically lowers RNA production costs, enabling products that previously were not commercially viable. GreenLight expects its first biopesticide to launch in 2022 and is pursuing a commercially available mRNA-based COVID-19 vaccine. The company highlights applications across plant, human, and animal health and emphasizes environmentally friendly crop protection that avoids residues and spares beneficial insects. GreenLight Biosciences is a Boston-based biotech that specializes in producing messenger RNA (mRNA) for vaccines. The company is focused on scaling mRNA manufacturing capacity to support the creation of "billions of doses" of potential COVID-19 vaccines for trials and potential deployment. GreenLight is also developing several versions of its own mRNA-based vaccine candidates targeting SARS-CoV-2. Some of the new funding will be used both to expand production capacity and to advance those vaccine candidates. The article characterizes mRNA vaccines as a relatively novel approach that contain no actual virus and can shorten pre-clinical development timelines. GreenLight raised special-purpose funding to support these manufacturing and development efforts. GreenLight Biosciences develops RNA products for plant and life science applications, focusing on agricultural bio-control products and human and animal vaccines and therapeutics. The company collaborates with industry leaders and academic institutions to advance vaccine development, pandemic preparation, crop management, and plant protection. Led by Co-Founder and CEO Andrey Zarur, GreenLight is expanding its discovery and development capabilities across multiple segments. The firm operates Plant Sciences R&D in RTP, NC and St. Louis, MO. Management says the work spans a portfolio of bio-performance candidates for plant and life sciences. The company intends to accelerate development through existing partnerships and the newly raised capital. GreenLight Biosciences develops RNA-based products for agriculture using its Cell-Free Bioprocessing® platform. The company focuses on dsRNA molecules designed to directly target insect and viral pests in high-value crops while sparing beneficial organisms and minimizing environmental impact. It is also developing additional RNA offerings in public health, vaccine development and human therapeutics. Led by Co-Founder and CEO Andrey J. Zarur, Ph.D., GreenLight plans to use new capital to accelerate development and field testing of several dsRNA molecules and to build up its team. The company recently completed a Series D financing and is based in Medford, Mass. GreenLight Biosciences is a Medford, Mass.-based developer of a cell-free approach to microbial chemical production. The company builds a bio-based manufacturing platform to produce chemicals from renewable, non-petroleum resources. Its core technology focuses on cell-free production methods intended to enable cleaner, scalable chemical manufacturing. GreenLight is led by Andrey Zarur, Ph.D., Co-Founder, CEO and Chairman. Financially, the company completed a Series C financing in July 2015; the amount was undisclosed. The round included participation from both new and existing investors and was led by MLS Capital Fund II.

Participated · Series C · Dec 2017

Lumicell is developing the LUM System, an integrated platform combining a fluorescent optical contrast agent, a handheld imaging device with single-cell detection, and proprietary decision software to guide surgeons in real time. The system is designed to detect and help remove residual cancer cells in the surgical cavity beyond the specimen margin, with the goal of reducing repeat surgeries and improving outcomes. Lumicell is investigating the LUM System in breast, prostate, colorectal, esophageal, and pancreatic cancer surgeries, with planned future indications including lung, ovarian, and brain cancers. The company highlights single-cell detection capability and instant image display to guide surgical removal. Advancement of the clinical pipeline and completion of breast cancer studies will be funded by a recently closed Series C financing.